News about Global Pharma

Syndax Announces Positive Revuforj Data in Acute Leukemias from Multiple Trials

Revuforj is the company's oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older.

Global Pharma | 09/12/2024 | By Aishwarya |  511

Suven Pharma to Acquire Stake in NJ Bio with Investment of USD 64.4 Million

NJ Bio has served 150+ customers, delivered over 500 projects in 5 years, and won the prestigious World ADC Awards for four consecutive years.

Global Pharma | 09/12/2024 | By Aishwarya |  435

Torrent Pharma Signs Deal with Boehringer Ingelheim to Acquire Three Anti-Diabetes Brands

Empagliflozin is a novel sodium-glucose co-transporter-2 (SGLT-2) inhibitor that is indicated for glycemic control in adults with type 2 diabetes mellitus.

Global Pharma | 09/12/2024 | By Aishwarya |  810

Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area

Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™.

Global Pharma | 07/12/2024 | By Aishwarya |  477

Alveron Pharma Secures EUR 5 Million in Seed Extension Financing

The capital provided by this new financing enables Alveron to accelerate important development activities that support OKL-1111’s readiness for further clinical studies to demonstrate safety and proof-of-concept efficacy in patients.

Global Pharma | 07/12/2024 | By Aishwarya |  252

Muna Therapeutics Partners with GSK to Develop Novel Treatments for Alzheimer's Disease

Together, Muna and GSK will assess postmortem human brain samples with spatial transcriptomics and other approaches to identify and validate potential new drug targets.

Global Pharma | 06/12/2024 | By Aishwarya |  275

Lupin Gets Approval from FDA for Abacavir, Dolutegravir and Lamivudine Tablets

Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension, 60 mg/5 mg/30 mg, (RLD Triumeq PD) had an estimated annual sale of USD 1.3 million in the US.

Global Pharma | 06/12/2024 | By Aishwarya |  695

Lilly to Invest USD 3 Billion to Expand its Manufacturing Facility in Wisconsin

Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.

Global Pharma | 06/12/2024 | By Aishwarya |  218

Phanes Secures Fast Track Designation for PT217 from FDA

PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, is being developed for the treatment of patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma, including neuroendocrine prostate cancer (NEPC).

Global Pharma | 05/12/2024 | By Aishwarya |  349

Orbit Discovery, Evergreen Theragnostics Expand Research Alliance to Boost Targeted Therapeutics Development

The expanded collaboration will leverage Orbit Discovery’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen Theragnostics’ expertise in radiopharmaceutical development and clinical translation.

Global Pharma | 04/12/2024 | By Aishwarya |  266